New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
07:11 EDTRGENRepligen raises FY14 revenue guidance to $59M-$62M from $58M-$61M
Consensus $59M. Total product revenue for 2014 is expected to be $57M-$60M, an increase from previous guidance of $56M-$59M. This reflects annual growth of 20%-26%. Product gross margin for FY14 is expected to be 53%-55%, an increase from our previous guidance of 51%-53%. Total income from operations for FY14 is expected to be $11M-$13M, increased from previous guidance of $10M-$12M. The company expects to end FY14 with $64M-$68M in cash and cash investments, an increase from our previous guidance of $62M-$66M.
News For RGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:35 EDTRGENPfizer issues to Repligen a notice of termination under 2012 license agreement
Subscribe for More Information
January 21, 2015
07:01 EDTRGENRepligen names COO Tony Hunt as next CEO
Repligen announced that its board has appointed Tony Hunt to be the company's next CEO. Mr. Hunt, currently Repligen's COO, will succeed Walter Herlihy, Ph.D., who will retire as president and CEO effective May 21, the date of the company's Annual Meeting of Stockholders.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use